

EVOLVING CONCEPTS IN ADPKD

Clinical presentations and
contemporary risk assessment

Dr. Frederic F. Rahbari-Oskoui

MD, MS, FASN

Dr. Michal Mrug

MD

THIS SESSION WILL ALSO INCLUDE
A ROUNDTABLE DISCUSSION

Available on demand

Thursday Oct 22nd – Friday Dec 4th, 2020



Dr. Frederic F. Rahbari-Oskoui *MD, MS, FASN*

Professor of Medicine, Nephrology,
Emory University School of Medicine, Atlanta, GA, USA

Dr. Rahbari-Oskoui is the director of Cystic Kidney Diseases Clinic at Emory University and a nephrologist practicing at Emory University Hospital, the Emory Clinic, and the Grady Memorial Hospital. He has co-authored more than 60 original manuscripts, review articles, textbook chapters and is a regular author for UpToDate on cystic diseases of the kidneys and polycystic kidney disease. He specializes in cystic diseases of the kidneys, inherited diseases of the kidneys, hypertension, ambulatory blood-pressure monitoring, and imaging in kidney diseases and he is involved in caring for patients with kidney diseases as well as conducting research in those fields. Dr. Rahbari-Oskoui is also an investigator in several landmark trials and observational cohorts.



Dr. Michal Mrug *MD*

Professor of Medicine, Nephrology,
University of Alabama at Birmingham (UAB), AL USA

Dr. Mrug co-founded and directs the UAB Polycystic Kidney Disease (PKD) Clinic and oversees clinical PKD research activities at UAB since 2009. This includes the CRISP study, an NIH-funded collaborative effort between Emory University, University of Kansas, Mayo Clinic, UAB and University of Pittsburgh that has led to many seminal discoveries. His clinical research interests are centered on the development of statistical models for prediction of the decline in the kidney function in patients with autosomal dominant polycystic kidney disease over time and better identification of those patients that may benefit most from therapeutic interventions. Dr. Mrug's basic research is focused on the identification of molecular pathways that modulate progression of renal cystic diseases, especially those related to inflammation. He also directs the Therapeutics Development and Screening Resource, one of four cores within the UAB Childhood Cystic Kidney Disease Core Center.

In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals. Accordingly, attendance by guests or spouses is not permitted. ©2020 Genzyme Corporation. All rights reserved. Sanofi and Genzyme are registered in the U.S. patent and trademark office.

Kidney Week 2020 Reimagined Exhibitor Spotlight